Sign inCreate account

Report workspace tools

NCT05851924RECRUITINGanonymous

Total Neoadjuvant NALIRIFOX Plus Ablative Dose Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Sponsor

Source record

Memorial Sloan Kettering Cancer Center

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Pancreatic Ductal Adenocarcinoma (PDAC)

Indication / condition

AI-normalized

Pancreatic Ductal Adenocarcinoma

Intervention

Source record

NALIRIFOX, AD-XRT and Capecitabine

Source & freshness

Source record

NCT ID

NCT05851924

Original source

ClinicalTrials.gov

Source last updated

Jun 05, 2025

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05851924

Title

Total Neoadjuvant NALIRIFOX Plus Ablative Dose Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Sponsor

Memorial Sloan Kettering Cancer Center

Status

RECRUITING

Phase

Phase 2

Condition raw

Pancreatic Ductal Adenocarcinoma

Condition normalized

Pancreatic Ductal Adenocarcinoma

Modality raw

Pancreatic Ductal Adenocarcinoma

Modality normalized

small molecule

Target raw

Pancreatic Ductal Adenocarcinoma (PDAC)

Target normalized

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

NALIRIFOX, AD-XRT and Capecitabine

Public preview

Source record

This clinical trial, sponsored by Memorial Sloan Kettering Cancer Center, investigates the efficacy of NALIRIFOX combined with ablative dose radiation therapy (AD-XRT) and capecitabine as a total neoadjuvant therapy for patients with borderline resectable and locally advanced PDAC. The study aims to assess treatment response, quality of life, and event-free survival in a single-arm design with an estimated enrollment of 60 participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Total Neoadjuvant NALIRIFOX Plus Ablative Dose Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05851924

Status

RECRUITING

Phase

Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Memorial Sloan Kettering Cancer Center, investigates the efficacy of NALIRIFOX combined with ablative dose radiation therapy (AD-XRT) and capecitabine as a total neoadjuvant therapy for patients with borderline resectable and locally advanced PDAC. The study aims to assess treatment response, quality of life, and event-free survival in a single-arm design with an estimated enrollment of 60 participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 05, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05851924

Indication

Pancreatic Ductal Adenocarcinoma

Modality

small molecule

Target

Pancreatic Ductal Adenocarcinoma (PDAC)

Intervention

NALIRIFOX, AD-XRT and Capecitabine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.